{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-24-000051","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.954167+00:00","generated_at":"2026-05-31T12:18:51.110429+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxcyte Q2 net loss $128.7M; cash $1.85B; VAX-31 adult data due Sept 2024","bullets":["Net loss $128.7M for Q2 2024 vs $68.3M in Q2 2023; R&D expenses $131.5M, up from $72.7M.","Cash, cash equivalents and investments $1,851.9M as of June 30, 2024, up from $1,242.9M at Dec 31, 2023.","VAX-31 adult Phase 1/2 topline safety and immunogenicity data expected in September 2024; will then select VAX-24 or VAX-31 for Phase 3.","VAX-24 infant Phase 2 topline from primary series due by end of Q1 2025; booster data by end of 2025.","Appointed John Furey to Board; received $9.5M NIAID grant for Chlamydia vaccine program."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-24-000051","json":"https://secwatch.observer/filing/0001649094-24-000051.json","markdown":"https://secwatch.observer/filing/0001649094-24-000051.md","text":"https://secwatch.observer/filing/0001649094-24-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909424000051/0001649094-24-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909424000051/pcvx-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:18:51.110429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}